Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Wright Reports
|
$472.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: ValuEngine, Inc.
|
$127.00
|
|
Provider: Thomson Reuters StreetEvents
|
$75.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Novozymes A/S Issues FY 2013 Guidance
Novozymes A/S announced that for the fiscal year 2013, the Company expects to report EBIT margin at its current high level, while organic sales growth is expected to increase to between 5% and 8%. For the fiscal year 2012, the Company reported EBIT margin at 24.4% and organic sales growth of 4%.
Latest Developments for Novozymes A/S
- Novozymes A/S Confirms FY 2013 Earnings Guidance and Raises FY 2013 Sales Guidance
- Novozymes A/S to Pay FY 2012 Dividend of DKK 2.20 Per Share
- Novozymes A/S Completes Acquisition of Enzymes Business from Iogen Corporation
- Novozymes A/S Acquires Enzyme Business from Iogen Corporation; Maintains FY 2013 Earnings Outlook
- Share this
- Link this
- Digg this
Follow Reuters